Linked Life Data

20066574

Source:http://linkedlifedata.com/resource/pubmed/id/20066574

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20066574rdf:typepubmed:Citationlld:pubmed
pubmed-article:20066574lifeskim:mentionsumls-concept:C0024299lld:lifeskim
pubmed-article:20066574lifeskim:mentionsumls-concept:C1257890lld:lifeskim
pubmed-article:20066574lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:20066574lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:20066574lifeskim:mentionsumls-concept:C0079731lld:lifeskim
pubmed-article:20066574lifeskim:mentionsumls-concept:C0393022lld:lifeskim
pubmed-article:20066574lifeskim:mentionsumls-concept:C1413947lld:lifeskim
pubmed-article:20066574lifeskim:mentionsumls-concept:C0205219lld:lifeskim
pubmed-article:20066574lifeskim:mentionsumls-concept:C0055598lld:lifeskim
pubmed-article:20066574lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:20066574lifeskim:mentionsumls-concept:C0936012lld:lifeskim
pubmed-article:20066574lifeskim:mentionsumls-concept:C0868928lld:lifeskim
pubmed-article:20066574lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:20066574lifeskim:mentionsumls-concept:C0022341lld:lifeskim
pubmed-article:20066574lifeskim:mentionsumls-concept:C1514923lld:lifeskim
pubmed-article:20066574pubmed:issue2lld:pubmed
pubmed-article:20066574pubmed:dateCreated2010-3-18lld:pubmed
pubmed-article:20066574pubmed:abstractTextWe performed a retrospective analysis of patients with diffuse large B cell lymphoma treated with rituximab plus CHOP (cyclophosphamide, adriamycin, vincristine and prednisone) as a first-line therapy at 22 hospitals of the Kyushu Lymphoma Study Group. During the period 1996-2005, 1,057 patients (aged 22-90 years) were analyzed. Of these, 678 were treated with CHOP, and 379 were treated with rituximab plus CHOP (R-CHOP). The complete response rate was 59.9% in the CHOP group and 67.0% in the R-CHOP group (P < 0.001). Three-year progression-free survival (PFS) and overall survival (OS) rates were significantly higher in the R-CHOP group than in the CHOP group (61.3 vs. 45.6% for PFS, P < 0.001; 68.3 vs. 54.5% for OS, P < 0.001). The International Prognostic Index was a good prognostic marker for both groups; a survival benefit of rituximab addition was found for each risk subgroup and also for both age groups (<or=60 and >60 years). Among 345 patients who received localized radiation therapy, the adding rituximab to CHOP attenuated the survival difference between CHOP and R-CHOP groups (P = 0.104), compared with no radiation group (P < 0.001). Results of this large-scale, multicenter study confirm that rituximab plus CHOP provided a greater survival benefit than CHOP alone.lld:pubmed
pubmed-article:20066574pubmed:languageenglld:pubmed
pubmed-article:20066574pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20066574pubmed:citationSubsetIMlld:pubmed
pubmed-article:20066574pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20066574pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20066574pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20066574pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20066574pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20066574pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20066574pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20066574pubmed:statusMEDLINElld:pubmed
pubmed-article:20066574pubmed:monthMarlld:pubmed
pubmed-article:20066574pubmed:issn1865-3774lld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:YoshidaMinoru...lld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:TaguchiFumihi...lld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:TsudaHiroyuki...lld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:SuzumiyaJunji...lld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:OkamuraTakash...lld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:OhshimaKoichi...lld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:AbeYasunobuYlld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:ShimodaKazuya...lld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:GondoHisashiHlld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:TamuraKazuoKlld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:SuzukiKeikoKlld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:UikeNaokuniNlld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:OgawaRyosukeRlld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:KawanoFumioFlld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:MoriuchiYukiy...lld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:UtsunomiyaAta...lld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:SuzushimaHito...lld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:MatsumotoTada...lld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:HiguchiMasaka...lld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:ImamuraYutaka...lld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:NagafujiKojiKlld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:SekiRitsukoRlld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:FujisakiTomoa...lld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:MakinoShigeyo...lld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:IwahashiMasah...lld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:KamimuraTomoh...lld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:YamashitaKiyo...lld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:EtoTetsuyaTlld:pubmed
pubmed-article:20066574pubmed:authorpubmed-author:TsukazakiKuni...lld:pubmed
pubmed-article:20066574pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20066574pubmed:volume91lld:pubmed
pubmed-article:20066574pubmed:ownerNLMlld:pubmed
pubmed-article:20066574pubmed:authorsCompleteYlld:pubmed
pubmed-article:20066574pubmed:pagination258-66lld:pubmed
pubmed-article:20066574pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:20066574pubmed:meshHeadingpubmed-meshheading:20066574...lld:pubmed
pubmed-article:20066574pubmed:meshHeadingpubmed-meshheading:20066574...lld:pubmed
pubmed-article:20066574pubmed:meshHeadingpubmed-meshheading:20066574...lld:pubmed
pubmed-article:20066574pubmed:meshHeadingpubmed-meshheading:20066574...lld:pubmed
pubmed-article:20066574pubmed:meshHeadingpubmed-meshheading:20066574...lld:pubmed
pubmed-article:20066574pubmed:meshHeadingpubmed-meshheading:20066574...lld:pubmed
pubmed-article:20066574pubmed:meshHeadingpubmed-meshheading:20066574...lld:pubmed
pubmed-article:20066574pubmed:meshHeadingpubmed-meshheading:20066574...lld:pubmed
pubmed-article:20066574pubmed:meshHeadingpubmed-meshheading:20066574...lld:pubmed
pubmed-article:20066574pubmed:meshHeadingpubmed-meshheading:20066574...lld:pubmed
pubmed-article:20066574pubmed:meshHeadingpubmed-meshheading:20066574...lld:pubmed
pubmed-article:20066574pubmed:meshHeadingpubmed-meshheading:20066574...lld:pubmed
pubmed-article:20066574pubmed:meshHeadingpubmed-meshheading:20066574...lld:pubmed
pubmed-article:20066574pubmed:meshHeadingpubmed-meshheading:20066574...lld:pubmed
pubmed-article:20066574pubmed:meshHeadingpubmed-meshheading:20066574...lld:pubmed
pubmed-article:20066574pubmed:meshHeadingpubmed-meshheading:20066574...lld:pubmed
pubmed-article:20066574pubmed:meshHeadingpubmed-meshheading:20066574...lld:pubmed
pubmed-article:20066574pubmed:meshHeadingpubmed-meshheading:20066574...lld:pubmed
pubmed-article:20066574pubmed:meshHeadingpubmed-meshheading:20066574...lld:pubmed
pubmed-article:20066574pubmed:meshHeadingpubmed-meshheading:20066574...lld:pubmed
pubmed-article:20066574pubmed:meshHeadingpubmed-meshheading:20066574...lld:pubmed
pubmed-article:20066574pubmed:year2010lld:pubmed
pubmed-article:20066574pubmed:articleTitleRituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group.lld:pubmed
pubmed-article:20066574pubmed:affiliationDivision of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.lld:pubmed
pubmed-article:20066574pubmed:publicationTypeJournal Articlelld:pubmed